Skip to main content

From the helm: Immutep’s (ASX:IMM) Executive Director & CEO, Marc Voigt

Jessica Amir
August 26, 2021

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Immutep’s (ASX:IMM) Executive Director and CEO, Marc Voigt.

Immutep has gained a lot of attention, as its trials in collaboration with big-names, Pfizer and Merck, has seen a remission in patients’ tumours. Between capital raisings and partnerships, Immutep continues to deliver impressive results…

In this video Marc discusses:

  • (0:40) IMM’s progress: the year that was, and the year ahead
  • (1:30) Promising results from an IMM study in collaboration with Pfizer and Merck
  • (2:29) Its unique discovery in immunotherapy – which spells new opportunities
  • (4:02) Key catalysts that could drive share price growth
  • (6:00) Fund managers who bought into IMM recently – and how funds raised will be spent

Weekly Wrap 27 June

Bell Direct
June 27, 2025

Morning Bell 26 June

Bell Direct
June 26, 2025

Morning Bell 25 June

Bell Direct
June 25, 2025

Morning Bell 24 June

Bell Direct
June 24, 2025

Morning Bell 23 June

Bell Direct
June 23, 2025

Weekly Wrap 20 June

Bell Direct
June 20, 2025

Morning Bell 19 June

Bell Direct
June 19, 2025

Morning Bell 18 June

Grady Wulff
June 18, 2025

Morning Bell 17 June

Sophia Mavridis
June 17, 2025

Morning Bell 16 June

Bell Direct
June 16, 2025

Weekly Wrap 13 June

Bell Direct
June 13, 2025